Modality
Cell Therapy
MOA
PI3Ki
Target
IL-13
Pathway
Lipid Met
SCD
Development Pipeline
Preclinical
~Mar 2020
→ ~Jun 2021
Phase 1
~Sep 2021
→ ~Dec 2022
Phase 2
Mar 2023
→ Apr 2031
Phase 2Current
NCT05325730
1,348 pts·SCD
2023-03→2031-04·Recruiting
1,348 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-04-105.0y awayPh2 Data· SCD
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2
Recruit…
Catalysts
Ph2 Data
2031-04-10 · 5.0y away
SCD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05325730 | Phase 2 | SCD | Recruiting | 1348 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 |